Endocrine Abstracts

Background: Although surgery is considered the first-line treatment for patients with endogenous Cushing’s syndrome (CS), medical therapy is often required to control severe hypercortisolism. Metyrapone and osilodrostat are inhibitors of 11β-hydroxylase that have not been directly compared yet.Methods: Retrospective analysis of patients with adrenocorticotropin (ACTH)-dependent and ACTH-independent CS treated with metyrapone or osilodrostat (as...

BackgroundAgouti related peptide (AgRP) is a neuropeptide, produced by the hypothalamus and by the adrenal glands. AgRP is an antagonist of proopiomelanocortin (POMC) and its principal role is to stimulate appetite. Although current evidences suggest that AgRP levels are influenced by glucocorticoids, it is still not clear, whether they depend on adrenocorticotropic hormone (ACTH) or cortisol. One of the aims of this study was to address this issue. Furt...

Background: Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in obese individuals. GLP-1 agonists, such as semaglutide, and SGLT-2 inhibitors, such as empagliflozin, are well known to be beneficial in NAFLD, while other incretins, like peptide tyrosine tyrosine 3-36 (PYY3-36), might be also useful for the treatment of NAFLD. We directly compared the effects of semaglutide alone and in combination with peptide tyrosine tyrosine 3-36 (PYY3-36), empagliflozin and...

Background: Bisphenol A (BPA) is known to act as an endocrine disruptor in different organs. However, its impact on adrenal gland functionality is largely unknown. This also applies to its substitute substances bisphenol F (BPF) and S (BPS). Therefore, experiments addressing this subject are urgently needed.Methods: The human adrenocortical cell lines NCI-H295R and MUC-1 were treated with increasing concentrations (1 nM – 1 mM) o...

Background: An activation of the hypothalamic-pituitary-adrenal (HPA) axis is a common observation in obese individuals. GLP-1 agonists, such as semaglutide, and SGLT-2 inhibitors, such as empagliflozin, are well known to be beneficial in obesity, while other incretins, like peptide tyrosine tyrosine 3-36 (PYY 3-36), might be also useful for the treatment of obesity. However, the effect of these substances on the adrenal gland is largely unknown. We directly compared the effec...

Background: Bisphenol A (BPA) acts as an endocrine disruptor in different endocrine systmes. However, its impact on the adrenal cortex and steroidogenesis is largely unknown. This also applies to its substitute substances bisphenol F (BPF) and S (BPS). Therefore, experiments addressing this subject are urgently needed.Methods: The human adrenocortical cell lines NCI-H295R and MUC-1 were treated with increasing concentrations (1 nM–1 mM) of bisphenol...

Adrenocortical carcinoma (ACC) is a rare malignant tumour with heterogeneous outcome. Prognostic classification relies on individual clinical/histopathological parameters that have limited performance. Recent studies proposed the use of selected DNA-based biomarkers to improve prognostication of ACC. Aim of the study was to perform a comparative analysis of DNA-based biomarkers (BM) for prognostic assessment of ACC by evaluating their added value to the established prognostic ...

Background: Combinatory treatments with analogues of incretins might mimic the beneficial effects of bariatric surgery. We could show in the past that a combinatory treatment with PYY 3-36 and liraglutide leads to a similar body weight loss as Roux-en-Y gastric bypass (RYGB). We hypothesize that a combination of semaglutide and a modified PYY 3-36 analogue with increased selectivity for the neuropeptide Y receptor type 2 (NNC0165-1273) exceeds the weight-reducing effects of ba...

Background: Circulating levels of the appetite-suppressing and glucoregulatory gut hormones glucagon-like peptide 1 (GLP-1) and peptide tyrosine tyrosine 3–36 (PYY3–36) are markedly increased after Roux-en-Y gastric bypass surgery (RYGB), which may contribute to some of its profound metabolic benefits in morbidly obese individuals.Objectives: To directly compare the metabolic effects of chronic systemic administration of the clinic...

Effects of Bariatric Surgery in Patients with CraniopharyngiomaObjectives: The prime objective of this study is the identification of the limiting factors of metabolic surgeries on weight reduction in patients with craniopharyngioma (CP) and consecutive hypothalamic obesity (HO).Patients: As of now, 37 patients were included, of which5 patients presented with HO and earlier bariatric surgery (mean BMI 50.44 kg/m2), ...